Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOR-C13 in advanced solid tumors
NCT03784677Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2019
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SOR-C13 in solid tumor (advanced stage), ovarian cancer, pancreatic cancer (PC) and 1 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events and serious adverse events, Incidence of >= grade 2 adverse events and 3 more. Started Jul 2019; status: completed.
02
Drugs
SOR-C13
03
Conditions
solid tumor (advanced stage)ovarian cancerpancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03784677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784677.